An Open Label, Randomized, Multi-Center, Phase IIIB, Parallel Group Switching Study to Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia.
Sponsor study identifier
Secondary identifiers
interventional
4,875
0 countries
N/A
Study Start
November 2001
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
September 2004
Actual (reported)The purpose of this study is to determine whether treatment with rosuvastatin following atorvastatin or simvastatin treatment will improve health outcomes for patients at high risk of Coronary heart disease compared to atorvastatin and simvastatin alone.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 2004
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 2001
Date type not reportedThis date has not been verified as actual or estimated.
September 2004
Actual (reported)April 3, 2008
Actual (reported)April 8, 2008
Actual (reported)Low density Lipoprotein cholesterol level - reaching internationally recognised LDL cholesterol goal levels.
16 weeks
Percentage change in other cholesterol & triglyceride measures
16 weeks
Safety evaluation
8 & 16 weeks
To compare the efficacy of rosuvastatin with atorvastatin and simvastatin
Rosuvastatin
Atorvastatin
Simvastatin
Ballantyne CM, Raichlen JS, Cain VA. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J Am Coll Cardiol. 2008 Aug 19;52(8):626-32. doi: 10.1016/j.jacc.2008.04.052.
Joel Raichlen
AstraZeneca
Russell Esterline
AstraZeneca
First Submitted
April 3, 2008
First Posted
April 8, 2008
Study Start
November 2001
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
September 2004
Actual (reported)Rosuvastatin ORBITAL Germany
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Last Updated
March 16, 2009
Record last verified: 2009-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: